Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Download PDF

    Clinical Trial Results:
    A double-blind, randomized, multicenter, placebo controlled, parallel group study to evaluate the efficacy and safety of fingolimod 0.5 mg administered orally once daily versus placebo in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) Due to EudraCT system limitations, which EMA is aware of, data using 999 as data points in this record are not an accurate representation of the clinical trial results. Please use https://www.novctrd.com/CtrdWeb/home.novfor complete trial results.

    Summary
    EudraCT number
    2011-005280-24
    Trial protocol
    BE   NL   DE   ES   GB   IT   GR   PL   CZ  
    Global end of trial date
    01 Sep 2016

    Results information
    Results version number
    v1(current)
    This version publication date
    08 Jul 2018
    First version publication date
    08 Jul 2018
    Other versions

    Trial information

    Close Top of page
    Trial identification
    Sponsor protocol code
    CFTY720I2201
    Additional study identifiers
    ISRCTN number
    -
    US NCT number
    NCT01625182
    WHO universal trial number (UTN)
    -
    Sponsors
    Sponsor organisation name
    Novartis Pharma AG
    Sponsor organisation address
    CH-4002, Basel, Switzerland,
    Public contact
    Clinical Disclosure Office, Novartis Pharma AG, 41 613241111,
    Scientific contact
    Clinical Disclosure Office, Novartis Pharma AG, 41 613241111,
    Paediatric regulatory details
    Is trial part of an agreed paediatric investigation plan (PIP)
    No
    Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?
    No
    Results analysis stage
    Analysis stage
    Final
    Date of interim/final analysis
    01 Sep 2016
    Is this the analysis of the primary completion data?
    No
    Global end of trial reached?
    Yes
    Global end of trial date
    01 Sep 2016
    Was the trial ended prematurely?
    Yes
    General information about the trial
    Main objective of the trial
    The primary objective of this study was to evaluate the effect of fingolimod 0.5 mg daily compared with placebo on delaying disability progression in patients with CIDP, measured by the time to the first confirmed worsening on the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale. A confirmed worsening was defined as an increase by 1 point or more on the adjusted INCAT Disability Scale from the value at baseline. Due to EudraCT system limitations, which EMA is aware of, data using 999 as data points in this record are not an accurate representation of the clinical trial results. Please use https://www.novctrd.com/CtrdWeb/home.novfor complete trial results.
    Protection of trial subjects
    The study was in compliance with the ethical principles derived from the Declaration of Helsinki and the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines. All the local regulatory requirements pertinent to safety of trial subjects were also followed during the conduct of the trial.
    Background therapy
    -
    Evidence for comparator
    -
    Actual start date of recruitment
    24 Jan 2014
    Long term follow-up planned
    No
    Independent data monitoring committee (IDMC) involvement?
    Yes
    Population of trial subjects
    Number of subjects enrolled per country
    Country: Number of subjects enrolled
    Australia: 4
    Country: Number of subjects enrolled
    Belgium: 8
    Country: Number of subjects enrolled
    Canada: 16
    Country: Number of subjects enrolled
    France: 12
    Country: Number of subjects enrolled
    Germany: 3
    Country: Number of subjects enrolled
    United Kingdom: 6
    Country: Number of subjects enrolled
    Greece: 2
    Country: Number of subjects enrolled
    Israel: 3
    Country: Number of subjects enrolled
    Italy: 5
    Country: Number of subjects enrolled
    Japan: 6
    Country: Number of subjects enrolled
    Netherlands: 4
    Country: Number of subjects enrolled
    Poland: 13
    Country: Number of subjects enrolled
    Spain: 10
    Country: Number of subjects enrolled
    United States: 14
    Worldwide total number of subjects
    106
    EEA total number of subjects
    63
    Number of subjects enrolled per age group
    In utero
    0
    Preterm newborn - gestational age < 37 wk
    0
    Newborns (0-27 days)
    0
    Infants and toddlers (28 days-23 months)
    0
    Children (2-11 years)
    0
    Adolescents (12-17 years)
    0
    Adults (18-64 years)
    87
    From 65 to 84 years
    19
    85 years and over
    0

    Subject disposition

    Close Top of page
    Recruitment
    Recruitment details
    -

    Pre-assignment
    Screening details
    Participants were assigned randomly to each treatment group in a 1:1 ratio.

    Period 1
    Period 1 title
    Overall Study (overall period)
    Is this the baseline period?
    Yes
    Allocation method
    Randomised - controlled
    Blinding used
    Double blind
    Roles blinded
    Subject, Investigator, Monitor, Carer, Data analyst, Assessor

    Arms
    Are arms mutually exclusive
    Yes

    Arm title
    Fingolimod (FTY720)
    Arm description
    Participants received Fingolimod 0.5 mg orally once daily.
    Arm type
    Experimental

    Investigational medicinal product name
    Fingolimod
    Investigational medicinal product code
    FTY720
    Other name
    Pharmaceutical forms
    Capsule
    Routes of administration
    Oral use
    Dosage and administration details
    Participants received fingolimod 0.5 mg orally once daily.

    Arm title
    Placebo
    Arm description
    Participants received matching placebo to Fingolimod orally once daily.
    Arm type
    Placebo

    Investigational medicinal product name
    Placebo
    Investigational medicinal product code
    Other name
    Pharmaceutical forms
    Capsule
    Routes of administration
    Oral use
    Dosage and administration details
    Participants received matching placebo to fingolimod orally once daily.

    Number of subjects in period 1
    Fingolimod (FTY720) Placebo
    Started
    54
    52
    Completed
    34
    41
    Not completed
    20
    11
         Consent withdrawn by subject
    5
    1
         Adverse event, non-fatal
    2
    -
         Protocol deviation
    -
    2
         Administrative problems
    1
    -
         Lack of efficacy
    12
    8

    Baseline characteristics

    Close Top of page
    Baseline characteristics reporting groups
    Reporting group title
    Fingolimod (FTY720)
    Reporting group description
    Participants received Fingolimod 0.5 mg orally once daily.

    Reporting group title
    Placebo
    Reporting group description
    Participants received matching placebo to Fingolimod orally once daily.

    Reporting group values
    Fingolimod (FTY720) Placebo Total
    Number of subjects
    54 52 106
    Age categorical
    Units: Subjects
        In utero
    0 0 0
        Preterm newborn infants (gestational age < 37 wks)
    0 0 0
        Newborns (0-27 days)
    0 0 0
        Infants and toddlers (28 days-23 months)
    0 0 0
        Children (2-11 years)
    0 0 0
        Adolescents (12-17 years)
    0 0 0
        Adults (18-64 years)
    43 44 87
        From 65-84 years
    11 8 19
        85 years and over
    0 0 0
    Age Continuous
    Units: Years
        arithmetic mean (standard deviation)
    54.3 ( 13.32 ) 54.6 ( 11.68 ) -
    Gender, Male/Female
    Units: Subjects
        Female
    17 22 39
        Male
    37 30 67

    End points

    Close Top of page
    End points reporting groups
    Reporting group title
    Fingolimod (FTY720)
    Reporting group description
    Participants received Fingolimod 0.5 mg orally once daily.

    Reporting group title
    Placebo
    Reporting group description
    Participants received matching placebo to Fingolimod orally once daily.

    Primary: Time to first confirmed worsening on the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale

    Close Top of page
    End point title
    Time to first confirmed worsening on the adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale
    End point description
    Confirmed worsening in CIDP was measured by the adjusted INCAT Disability Scale. The adjusted INCAT disability scale measures arm disability and leg disability. For arm disability the scale ranges from 0 (no upper limb problems) to 5 (inability to use either arm for any purposeful movement). The leg disability scale ranges from 0 (walking not affected) to 5 (restricted to wheelchair, unable to stand and walk a few steps with help). The total adjusted INCAT disability score is calculated s the sum of the arm and leg disability scores where the total score ranges from 0 to 10. A confirmed worsening was defined as an increase by 1 or more points on the adjusted INCAT disability scale from the value at baseline.
    End point type
    Primary
    End point timeframe
    Month 12
    End point values
    Fingolimod (FTY720) Placebo
    Number of subjects analysed
    54
    52
    Units: Days
        median (confidence interval 95%)
    721 (159 to 9999)
    540 (183 to 9999)
    Statistical analysis title
    Time to first confirmed worsening event
    Statistical analysis description
    Survival analysis of time to first confirmed worsening event by adjusted INCAT disability scale
    Comparison groups
    Fingolimod (FTY720) v Placebo
    Number of subjects included in analysis
    106
    Analysis specification
    Pre-specified
    Analysis type
    P-value
    = 0.9838
    Method
    Regression, Cox
    Parameter type
    Hazard ratio (HR)
    Point estimate
    1
    Confidence interval
         level
    95%
         sides
    2-sided
         lower limit
    0.6
         upper limit
    1.7

    Secondary: Change from Baseline for grip strength, dominant hand

    Close Top of page
    End point title
    Change from Baseline for grip strength, dominant hand
    End point description
    Grip strength measurements were done using a vigorimeter. With this device, the pressure in the bulb exercised by the participant was registered on a manometer via a rubber junction tube. Both the dominant and non-dominant hands were tested. A negative change from baseline indicates deterioration.
    End point type
    Secondary
    End point timeframe
    Month 6, Month 12
    End point values
    Fingolimod (FTY720) Placebo
    Number of subjects analysed
    53
    50
    Units: kPa
    least squares mean (confidence interval 95%)
        Month 6
    -2.6 (-8.09 to 2.8)
    -3.8 (-9.37 to 1.7)
        Month 12
    -0.8 (-6.47 to 4.96)
    -3.9 (-9.68 to 1.94)
    No statistical analyses for this end point

    Secondary: Change from Baseline for grip strength, non-dominant hand

    Close Top of page
    End point title
    Change from Baseline for grip strength, non-dominant hand
    End point description
    Grip strength measurements were done using a vigorimeter. With this device, the pressure in the bulb exercised by the participant was registered on a manometer via a rubber junction tube. Both the dominant and non-dominant hands were tested. A negative change from baseline indicates deterioration.
    End point type
    Secondary
    End point timeframe
    Month 6, Month 12
    End point values
    Fingolimod (FTY720) Placebo
    Number of subjects analysed
    53
    50
    Units: kPa
    least squares mean (confidence interval 95%)
        Month 6
    -2.7 (-8.13 to 2.66)
    -6.1 (-11.59 to -0.66)
        Month 12
    -1.2 (-6.69 to 4.37)
    -5 (-10.57 to 0.64)
    No statistical analyses for this end point

    Secondary: Change from Baseline for Rasch-Built Linearly Weighted Overall Disability Scale (R-ODS)

    Close Top of page
    End point title
    Change from Baseline for Rasch-Built Linearly Weighted Overall Disability Scale (R-ODS)
    End point description
    This questionnaire was constructed using the patients’ perception of their ability to perform daily and social activities. The questionnaire comprises 24 items ranging from ability to read a book or newspaper (as the easiest item to accomplish) to ability to run (most difficult item to accomplish). The obtained raw summed score was translated subsequently to a convenient centile metric score ranging from 0 (most severe disability) to 100 (no disability at all). A higher score indicated a better health status. A negative change from baseline indicates deterioration.
    End point type
    Secondary
    End point timeframe
    Month 6, Month 12
    End point values
    Fingolimod (FTY720) Placebo
    Number of subjects analysed
    54
    51
    Units: score on a scale
    least squares mean (confidence interval 95%)
        Month 6
    -6.4 (-9.57 to -3.15)
    -5.5 (-8.89 to -2.21)
        Month 12
    -5.7 (-9.07 to -2.37)
    -5.1 (-8.54 to -1.57)
    No statistical analyses for this end point

    Adverse events

    Close Top of page
    Adverse events information
    Timeframe for reporting adverse events
    Adverse events are collected from First Patient First Visit (FPFV) until Last Patient Last Visit (LPLV). All adverse events reported in this record are from date of First Patient First Treatment until Last Patient Last Visit.
    Adverse event reporting additional description
    AE additional description
    Assessment type
    Systematic
    Dictionary used for adverse event reporting
    Dictionary name
    MedDRA
    Dictionary version
    19.0
    Reporting groups
    Reporting group title
    Fingolimod 0.5 mg
    Reporting group description
    Fingolimod 0.5 mg

    Reporting group title
    All@patients
    Reporting group description
    All@patients

    Reporting group title
    Placebo
    Reporting group description
    Placebo

    Serious adverse events
    Fingolimod 0.5 mg All@patients Placebo
    Total subjects affected by serious adverse events
         subjects affected / exposed
    9 / 54 (16.67%)
    13 / 106 (12.26%)
    4 / 52 (7.69%)
         number of deaths (all causes)
    0
    0
    0
         number of deaths resulting from adverse events
    0
    0
    0
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Breast cancer
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Gastric cancer
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Retroperitoneal cancer
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Injury, poisoning and procedural complications
    Ankle fracture
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Vascular disorders
    Vasculitis
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Nervous system disorders
    Cauda equina syndrome
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Chronic inflammatory demyelinating polyradiculoneuropathy
         subjects affected / exposed
    2 / 54 (3.70%)
    3 / 106 (2.83%)
    1 / 52 (1.92%)
         occurrences causally related to treatment / all
    1 / 2
    1 / 3
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Guillain-Barre syndrome
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    General disorders and administration site conditions
    Oedema peripheral
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Renal and urinary disorders
    Nephrolithiasis
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences causally related to treatment / all
    0 / 0
    0 / 1
    0 / 1
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Musculoskeletal and connective tissue disorders
    Bursitis
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences causally related to treatment / all
    1 / 1
    1 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Infections and infestations
    Abdominal sepsis
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Cellulitis
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences causally related to treatment / all
    0 / 1
    0 / 1
    0 / 0
         deaths causally related to treatment / all
    0 / 0
    0 / 0
    0 / 0
    Frequency threshold for reporting non-serious adverse events: 0%
    Non-serious adverse events
    Fingolimod 0.5 mg All@patients Placebo
    Total subjects affected by non serious adverse events
         subjects affected / exposed
    40 / 54 (74.07%)
    82 / 106 (77.36%)
    42 / 52 (80.77%)
    Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    Acrochordon
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Fibrous histiocytoma
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Haemangioma
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Haemangioma of skin
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Malignant melanoma in situ
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Melanocytic naevus
         subjects affected / exposed
    2 / 54 (3.70%)
    3 / 106 (2.83%)
    1 / 52 (1.92%)
         occurrences all number
    2
    4
    2
    Seborrhoeic keratosis
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Skin papilloma
         subjects affected / exposed
    1 / 54 (1.85%)
    2 / 106 (1.89%)
    1 / 52 (1.92%)
         occurrences all number
    1
    2
    1
    Uterine leiomyoma
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Vascular disorders
    Hot flush
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Hypertension
         subjects affected / exposed
    10 / 54 (18.52%)
    11 / 106 (10.38%)
    1 / 52 (1.92%)
         occurrences all number
    10
    11
    1
    General disorders and administration site conditions
    Adverse drug reaction
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Asthenia
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Chest discomfort
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Discomfort
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Fatigue
         subjects affected / exposed
    4 / 54 (7.41%)
    10 / 106 (9.43%)
    6 / 52 (11.54%)
         occurrences all number
    4
    10
    6
    Influenza like illness
         subjects affected / exposed
    1 / 54 (1.85%)
    2 / 106 (1.89%)
    1 / 52 (1.92%)
         occurrences all number
    1
    2
    1
    Local swelling
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Oedema peripheral
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Pain
         subjects affected / exposed
    1 / 54 (1.85%)
    2 / 106 (1.89%)
    1 / 52 (1.92%)
         occurrences all number
    1
    2
    1
    Peripheral swelling
         subjects affected / exposed
    1 / 54 (1.85%)
    2 / 106 (1.89%)
    1 / 52 (1.92%)
         occurrences all number
    1
    2
    1
    Pyrexia
         subjects affected / exposed
    2 / 54 (3.70%)
    3 / 106 (2.83%)
    1 / 52 (1.92%)
         occurrences all number
    2
    4
    2
    Immune system disorders
    Drug hypersensitivity
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Reproductive system and breast disorders
    Breast cyst
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Breast pain
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Breast swelling
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Dysfunctional uterine bleeding
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Respiratory, thoracic and mediastinal disorders
    Bronchial obstruction
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Cough
         subjects affected / exposed
    1 / 54 (1.85%)
    2 / 106 (1.89%)
    1 / 52 (1.92%)
         occurrences all number
    1
    2
    1
    Dyspnoea
         subjects affected / exposed
    1 / 54 (1.85%)
    2 / 106 (1.89%)
    1 / 52 (1.92%)
         occurrences all number
    1
    2
    1
    Dyspnoea exertional
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Epistaxis
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Nasal congestion
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Oropharyngeal pain
         subjects affected / exposed
    1 / 54 (1.85%)
    4 / 106 (3.77%)
    3 / 52 (5.77%)
         occurrences all number
    1
    4
    3
    Rhinitis allergic
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Rhinorrhoea
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Psychiatric disorders
    Abnormal dreams
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Anxiety
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Hallucination
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Insomnia
         subjects affected / exposed
    1 / 54 (1.85%)
    5 / 106 (4.72%)
    4 / 52 (7.69%)
         occurrences all number
    1
    6
    5
    Irritability
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Investigations
    Alanine aminotransferase increased
         subjects affected / exposed
    2 / 54 (3.70%)
    3 / 106 (2.83%)
    1 / 52 (1.92%)
         occurrences all number
    2
    4
    2
    Amylase increased
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Aspartate aminotransferase increased
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Blood alkaline phosphatase increased
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Blood cholesterol increased
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Blood urine present
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Carbon monoxide diffusing capacity decreased
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Cardiac murmur
         subjects affected / exposed
    1 / 54 (1.85%)
    2 / 106 (1.89%)
    1 / 52 (1.92%)
         occurrences all number
    1
    2
    1
    Gamma-glutamyltransferase increased
         subjects affected / exposed
    3 / 54 (5.56%)
    3 / 106 (2.83%)
    0 / 52 (0.00%)
         occurrences all number
    3
    3
    0
    Glycosylated haemoglobin increased
         subjects affected / exposed
    1 / 54 (1.85%)
    2 / 106 (1.89%)
    1 / 52 (1.92%)
         occurrences all number
    1
    2
    1
    Grip strength decreased
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Heart rate increased
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Hepatic enzyme increased
         subjects affected / exposed
    2 / 54 (3.70%)
    2 / 106 (1.89%)
    0 / 52 (0.00%)
         occurrences all number
    2
    2
    0
    Hepatitis A virus test positive
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Occult blood
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Optic nerve cup/disc ratio increased
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Pulmonary function test decreased
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Serum ferritin decreased
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Injury, poisoning and procedural complications
    Back injury
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Concussion
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Excoriation
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Fall
         subjects affected / exposed
    4 / 54 (7.41%)
    5 / 106 (4.72%)
    1 / 52 (1.92%)
         occurrences all number
    4
    5
    1
    Foot fracture
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Hand fracture
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Infusion related reaction
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Joint dislocation
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Joint injury
         subjects affected / exposed
    1 / 54 (1.85%)
    2 / 106 (1.89%)
    1 / 52 (1.92%)
         occurrences all number
    1
    2
    1
    Ligament sprain
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Limb injury
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Muscle hernia
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Muscle strain
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Post-traumatic pain
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    2
    2
    Procedural headache
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Procedural pain
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Tooth fracture
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Wound
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Wrist fracture
         subjects affected / exposed
    0 / 54 (0.00%)
    2 / 106 (1.89%)
    2 / 52 (3.85%)
         occurrences all number
    0
    2
    2
    Congenital, familial and genetic disorders
    Ventricular septal defect
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Cardiac disorders
    Palpitations
         subjects affected / exposed
    1 / 54 (1.85%)
    2 / 106 (1.89%)
    1 / 52 (1.92%)
         occurrences all number
    1
    2
    1
    Tachycardia
         subjects affected / exposed
    0 / 54 (0.00%)
    2 / 106 (1.89%)
    2 / 52 (3.85%)
         occurrences all number
    0
    2
    2
    Nervous system disorders
    Amnesia
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Coordination abnormal
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Dizziness
         subjects affected / exposed
    3 / 54 (5.56%)
    5 / 106 (4.72%)
    2 / 52 (3.85%)
         occurrences all number
    5
    8
    3
    Dysgeusia
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Headache
         subjects affected / exposed
    12 / 54 (22.22%)
    20 / 106 (18.87%)
    8 / 52 (15.38%)
         occurrences all number
    13
    22
    9
    Hypoaesthesia
         subjects affected / exposed
    2 / 54 (3.70%)
    4 / 106 (3.77%)
    2 / 52 (3.85%)
         occurrences all number
    2
    4
    2
    Memory impairment
         subjects affected / exposed
    1 / 54 (1.85%)
    2 / 106 (1.89%)
    1 / 52 (1.92%)
         occurrences all number
    1
    2
    1
    Meningism
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Migraine
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Neuralgia
         subjects affected / exposed
    0 / 54 (0.00%)
    2 / 106 (1.89%)
    2 / 52 (3.85%)
         occurrences all number
    0
    2
    2
    Neuropathy peripheral
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Paraesthesia
         subjects affected / exposed
    5 / 54 (9.26%)
    5 / 106 (4.72%)
    0 / 52 (0.00%)
         occurrences all number
    6
    6
    0
    Parkinsonism
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Sciatica
         subjects affected / exposed
    2 / 54 (3.70%)
    3 / 106 (2.83%)
    1 / 52 (1.92%)
         occurrences all number
    4
    5
    1
    Somnolence
         subjects affected / exposed
    1 / 54 (1.85%)
    3 / 106 (2.83%)
    2 / 52 (3.85%)
         occurrences all number
    1
    3
    2
    Syncope
         subjects affected / exposed
    2 / 54 (3.70%)
    3 / 106 (2.83%)
    1 / 52 (1.92%)
         occurrences all number
    2
    3
    1
    Tremor
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    2
    2
    0
    Blood and lymphatic system disorders
    Anaemia
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Leukopenia
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    2
    2
    0
    Ear and labyrinth disorders
    Ear pain
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Tinnitus
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Vertigo
         subjects affected / exposed
    3 / 54 (5.56%)
    6 / 106 (5.66%)
    3 / 52 (5.77%)
         occurrences all number
    3
    7
    4
    Eye disorders
    Blepharitis
         subjects affected / exposed
    2 / 54 (3.70%)
    2 / 106 (1.89%)
    0 / 52 (0.00%)
         occurrences all number
    2
    2
    0
    Cataract
         subjects affected / exposed
    1 / 54 (1.85%)
    4 / 106 (3.77%)
    3 / 52 (5.77%)
         occurrences all number
    1
    4
    3
    Diplopia
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Eye pain
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Eye pruritus
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Iritis
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Macular oedema
         subjects affected / exposed
    1 / 54 (1.85%)
    2 / 106 (1.89%)
    1 / 52 (1.92%)
         occurrences all number
    1
    2
    1
    Meibomianitis
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Metamorphopsia
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Retinal disorder
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Retinoschisis
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Subretinal fluid
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Vision blurred
         subjects affected / exposed
    2 / 54 (3.70%)
    2 / 106 (1.89%)
    0 / 52 (0.00%)
         occurrences all number
    2
    2
    0
    Visual acuity reduced
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Visual impairment
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Vitreous detachment
         subjects affected / exposed
    1 / 54 (1.85%)
    2 / 106 (1.89%)
    1 / 52 (1.92%)
         occurrences all number
    1
    2
    1
    Vitreous floaters
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Gastrointestinal disorders
    Abdominal discomfort
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Abdominal distension
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Abdominal mass
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Abdominal pain
         subjects affected / exposed
    1 / 54 (1.85%)
    2 / 106 (1.89%)
    1 / 52 (1.92%)
         occurrences all number
    1
    2
    1
    Abdominal pain upper
         subjects affected / exposed
    2 / 54 (3.70%)
    3 / 106 (2.83%)
    1 / 52 (1.92%)
         occurrences all number
    2
    3
    1
    Change of bowel habit
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Chronic gastritis
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Constipation
         subjects affected / exposed
    1 / 54 (1.85%)
    2 / 106 (1.89%)
    1 / 52 (1.92%)
         occurrences all number
    1
    2
    1
    Diarrhoea
         subjects affected / exposed
    3 / 54 (5.56%)
    5 / 106 (4.72%)
    2 / 52 (3.85%)
         occurrences all number
    3
    5
    2
    Dry mouth
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Dyspepsia
         subjects affected / exposed
    1 / 54 (1.85%)
    2 / 106 (1.89%)
    1 / 52 (1.92%)
         occurrences all number
    1
    2
    1
    Dysphagia
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Food poisoning
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Gastrointestinal disorder
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Gastrooesophageal reflux disease
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Gingival cyst
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Gingival hyperplasia
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Nausea
         subjects affected / exposed
    2 / 54 (3.70%)
    8 / 106 (7.55%)
    6 / 52 (11.54%)
         occurrences all number
    2
    8
    6
    Oesophagitis
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Periodontal disease
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Tooth disorder
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Tooth loss
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Hepatobiliary disorders
    Hepatic function abnormal
         subjects affected / exposed
    1 / 54 (1.85%)
    2 / 106 (1.89%)
    1 / 52 (1.92%)
         occurrences all number
    1
    2
    1
    Liver disorder
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Skin and subcutaneous tissue disorders
    Actinic keratosis
         subjects affected / exposed
    1 / 54 (1.85%)
    4 / 106 (3.77%)
    3 / 52 (5.77%)
         occurrences all number
    4
    7
    3
    Alopecia
         subjects affected / exposed
    2 / 54 (3.70%)
    3 / 106 (2.83%)
    1 / 52 (1.92%)
         occurrences all number
    2
    3
    1
    Chloasma
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Dermatitis
         subjects affected / exposed
    1 / 54 (1.85%)
    2 / 106 (1.89%)
    1 / 52 (1.92%)
         occurrences all number
    1
    2
    1
    Dermatitis allergic
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Dermatitis contact
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Dry skin
         subjects affected / exposed
    1 / 54 (1.85%)
    3 / 106 (2.83%)
    2 / 52 (3.85%)
         occurrences all number
    1
    3
    2
    Eczema
         subjects affected / exposed
    1 / 54 (1.85%)
    2 / 106 (1.89%)
    1 / 52 (1.92%)
         occurrences all number
    2
    4
    2
    Erythema
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Idiopathic urticaria
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Ingrowing nail
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Intertrigo
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Lentigo
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Night sweats
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Onycholysis
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Petechiae
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    2
    2
    0
    Pityriasis rosea
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Pruritus
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Rash
         subjects affected / exposed
    2 / 54 (3.70%)
    5 / 106 (4.72%)
    3 / 52 (5.77%)
         occurrences all number
    2
    5
    3
    Rash erythematous
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    2
    2
    0
    Rash generalised
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Rash pruritic
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Rosacea
         subjects affected / exposed
    1 / 54 (1.85%)
    2 / 106 (1.89%)
    1 / 52 (1.92%)
         occurrences all number
    1
    2
    1
    Seborrhoeic dermatitis
         subjects affected / exposed
    0 / 54 (0.00%)
    3 / 106 (2.83%)
    3 / 52 (5.77%)
         occurrences all number
    0
    3
    3
    Skin fissures
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Skin lesion
         subjects affected / exposed
    2 / 54 (3.70%)
    4 / 106 (3.77%)
    2 / 52 (3.85%)
         occurrences all number
    2
    4
    2
    Urticaria
         subjects affected / exposed
    2 / 54 (3.70%)
    3 / 106 (2.83%)
    1 / 52 (1.92%)
         occurrences all number
    2
    3
    1
    Renal and urinary disorders
    Cystitis noninfective
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    2
    2
    Dysuria
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Urinary tract inflammation
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Endocrine disorders
    Cushingoid
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Hypothyroidism
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Musculoskeletal and connective tissue disorders
    Arthralgia
         subjects affected / exposed
    1 / 54 (1.85%)
    3 / 106 (2.83%)
    2 / 52 (3.85%)
         occurrences all number
    1
    3
    2
    Arthritis
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Arthropathy
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Back pain
         subjects affected / exposed
    4 / 54 (7.41%)
    7 / 106 (6.60%)
    3 / 52 (5.77%)
         occurrences all number
    4
    8
    4
    Bursitis
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Exostosis
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Joint swelling
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Monarthritis
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Muscle spasms
         subjects affected / exposed
    2 / 54 (3.70%)
    3 / 106 (2.83%)
    1 / 52 (1.92%)
         occurrences all number
    2
    3
    1
    Muscle twitching
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Muscular weakness
         subjects affected / exposed
    2 / 54 (3.70%)
    4 / 106 (3.77%)
    2 / 52 (3.85%)
         occurrences all number
    4
    7
    3
    Musculoskeletal pain
         subjects affected / exposed
    2 / 54 (3.70%)
    3 / 106 (2.83%)
    1 / 52 (1.92%)
         occurrences all number
    2
    3
    1
    Musculoskeletal stiffness
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Myalgia
         subjects affected / exposed
    1 / 54 (1.85%)
    2 / 106 (1.89%)
    1 / 52 (1.92%)
         occurrences all number
    1
    2
    1
    Neck mass
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Neck pain
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Osteoarthritis
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Pain in extremity
         subjects affected / exposed
    7 / 54 (12.96%)
    10 / 106 (9.43%)
    3 / 52 (5.77%)
         occurrences all number
    7
    12
    5
    Rheumatoid arthritis
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Spinal column stenosis
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Synovial cyst
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Tendon pain
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Tendonitis
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Torticollis
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Infections and infestations
    Bronchitis
         subjects affected / exposed
    3 / 54 (5.56%)
    4 / 106 (3.77%)
    1 / 52 (1.92%)
         occurrences all number
    4
    5
    1
    Candida infection
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Catheter site infection
         subjects affected / exposed
    0 / 54 (0.00%)
    2 / 106 (1.89%)
    2 / 52 (3.85%)
         occurrences all number
    0
    2
    2
    Diverticulitis
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Ear infection
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Folliculitis
         subjects affected / exposed
    2 / 54 (3.70%)
    5 / 106 (4.72%)
    3 / 52 (5.77%)
         occurrences all number
    2
    5
    3
    Gastroenteritis
         subjects affected / exposed
    0 / 54 (0.00%)
    2 / 106 (1.89%)
    2 / 52 (3.85%)
         occurrences all number
    0
    2
    2
    Gastroenteritis viral
         subjects affected / exposed
    1 / 54 (1.85%)
    2 / 106 (1.89%)
    1 / 52 (1.92%)
         occurrences all number
    1
    2
    1
    Herpes zoster
         subjects affected / exposed
    1 / 54 (1.85%)
    2 / 106 (1.89%)
    1 / 52 (1.92%)
         occurrences all number
    1
    2
    1
    Influenza
         subjects affected / exposed
    2 / 54 (3.70%)
    2 / 106 (1.89%)
    0 / 52 (0.00%)
         occurrences all number
    3
    3
    0
    Laryngitis
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Meningitis aseptic
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Nasopharyngitis
         subjects affected / exposed
    6 / 54 (11.11%)
    13 / 106 (12.26%)
    7 / 52 (13.46%)
         occurrences all number
    16
    33
    17
    Onychomycosis
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Oral herpes
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    4
    4
    0
    Parasitic gastroenteritis
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Periodontitis
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Pharyngitis
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Pharyngotonsillitis
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Sinusitis
         subjects affected / exposed
    1 / 54 (1.85%)
    2 / 106 (1.89%)
    1 / 52 (1.92%)
         occurrences all number
    1
    2
    1
    Tinea cruris
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Tinea infection
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Tonsillitis bacterial
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Tooth infection
         subjects affected / exposed
    0 / 54 (0.00%)
    2 / 106 (1.89%)
    2 / 52 (3.85%)
         occurrences all number
    0
    2
    2
    Upper respiratory tract infection
         subjects affected / exposed
    1 / 54 (1.85%)
    3 / 106 (2.83%)
    2 / 52 (3.85%)
         occurrences all number
    1
    4
    3
    Urinary tract infection
         subjects affected / exposed
    3 / 54 (5.56%)
    4 / 106 (3.77%)
    1 / 52 (1.92%)
         occurrences all number
    4
    5
    1
    Vulvovaginal candidiasis
         subjects affected / exposed
    1 / 54 (1.85%)
    2 / 106 (1.89%)
    1 / 52 (1.92%)
         occurrences all number
    1
    2
    1
    Wound infection
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Metabolism and nutrition disorders
    Decreased appetite
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Dyslipidaemia
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Fluid retention
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Hypercholesterolaemia
         subjects affected / exposed
    1 / 54 (1.85%)
    1 / 106 (0.94%)
    0 / 52 (0.00%)
         occurrences all number
    1
    1
    0
    Increased appetite
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1
    Vitamin D deficiency
         subjects affected / exposed
    0 / 54 (0.00%)
    1 / 106 (0.94%)
    1 / 52 (1.92%)
         occurrences all number
    0
    1
    1

    More information

    Close Top of page

    Substantial protocol amendments (globally)

    Were there any global substantial amendments to the protocol? Yes
    Date
    Amendment
    18 Jan 2013
    Additional randomization stratification was introduced within 2 regions (Japan and countries outside Japan) to ensure balance of treatment assignments within Japan and globally; Clarification on the CIDP diagnosis was included in inclusion criteria to specify the European Federation of Neurological Societies/Peripheral Nerve Society criteria; A minimum glomerular filtration rate value was added to exclude patients with severe renal impairment. For assessments during the study the following key clarifications were provided: during ophthalmologic examination an OCT was to be performed at Screening to detect macular edema. The lower limits for clinically notable high values for SBP and DBP were updated. Clarification and guidance were provided for the management of patients with elevated liver function tests and lymphopenia.
    06 Sep 2013
    Directions were added that patients receiving corticosteroids were to be administered antiviral prophylaxis during corticosteroid taper period and for 4 weeks after the end of the taper period; Confirmation was added that if medically appropriate, corticosteroid treatment was to be initiated 6 or more weeks after stopping study drug. If treatment was needed during the first 6 weeks following study drug discontinuation, antiviral prophylaxis was to be initiated and continued until at least 6 weeks after the last dose of study drug. Information regarding antiviral prophylactic treatment in the “Risks and benefits” section was updated; Inclusion and exclusion criteria were updated to allow patients to enter the study who had a documented history of clinically meaningful deterioration within 1 year prior to Screening during therapy or following interruption or reduction of therapy. Exclusion criteria were updated to clarify that patients who presented with a current diagnosis of diabetes (including steroid-induced diabetes) were excluded but that patients with a history of diabetes (steroid-induced diabetes or gestational diabetes) were eligible if diabetes was controlled. The list of excluded treatments was updated. New text was added to update the criteria for liver events and management of patients with lymphopenia.
    10 Oct 2013
    The term multiple sclerosis was corrected and replaced by CIDP in one exclusion criterion.
    22 Jul 2014
    Exclusion criterion was updated to allow enrollment of patients with controlled diabetes mellitus who met electrophysiological criteria for demyelinating neuropathy and had documented clinically meaningful response to treatment with steroids, IVIg, or PE within the previous year.
    05 May 2015
    The time required to reach the minimum number of events was re-estimated, based on the current recruitment rate thus the maximum duration of the study was modified from 3 to approximately 4.5 years. The guidance of monitoring patients with infections was updated with additional guidance for early diagnosis and treatment of cryptococcal meningitis, should it have occurred. Guidance on study drug administration was updated to align with the current fingolimod prescribing information. Minor clarifications of exclusion criteria were provided; Criterion referring to CIDP history was revised: history of documented clinically meaningful deterioration, was revised from 1 year to 18 months. Inclusion criterion referring to stable CIDP symptoms before randomization without significant change in treatment regimen, was revised from 2 months to 6 weeks.

    Interruptions (globally)

    Were there any global interruptions to the trial? No

    Limitations and caveats

    Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data.
    The pre-planned interim analysis for futility revealed an unsatisfactory therapeutic effect of fingolimod in patients with CIDP. Therefore, the DMC recommended an early termination of this study and patients were brought in for a close-out visit.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 01 18:08:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA